ABSTRACT
OBJECTIVE: New insights into mechanisms should enable strategic improvement of allergen immunotherapy, aiming to make it safer, faster, more effective, and able to induce long-term tolerance. We review novel approaches with potential to translate into clinical use. DATA SOURCES: Database searches were conducted in PubMed, Scopus, and Google Scholar. STUDY SELECTIONS: Search terms were based on current and novel approaches in immunotherapy. Literature was selected primarily from recent randomized double-blinded placebo-controlled trials and meta-analyses. RESULTS: Alum, microcrystalline tyrosine, and calcium phosphate are adjuvants in current use. Toll-like receptor-4 agonists combined with allergen have potential to shorten duration of treatment. Other novel adjuvants, nanoparticles, and virus-like particles in combination with allergen have shown early promise. Omalizumab lessens systemic side effects but does not improve efficacy. Intralymphatic immunotherapy for aeroallergens, epicutaneous immunotherapy for food allergens, and use of modified allergens (allergoids), recombinant allergens (and hypoallergenic variants), and T- and B-cell peptide approaches have shown evidence of efficacy and permitted shortened courses but have only rarely been compared with conventional extracts. CONCLUSION: Novel routes of immunotherapy, use of modified allergens, and combination of allergens with immunostimulatory adjuvants or immune modifiers have been developed to augment downregulation of T-helper cell type 2 immunity and/or induce "protective" blocking antibodies. Although these strategies have permitted shortened courses, confirmatory phase 3 trials are required to confirm efficacy and safety and head-to-head trials are required for comparative efficacy. Currently, subcutaneous and sublingual immunotherapies using in-house standardized crude extracts remain the only approaches proved to induce long-term tolerance.
Subject(s)
Allergens/therapeutic use , Food Hypersensitivity/therapy , Sublingual Immunotherapy/methods , Allergens/administration & dosage , Epitopes, T-Lymphocyte/immunology , Humans , Immune Tolerance/immunology , Injections, SubcutaneousSubject(s)
Complement Activation/immunology , Complement System Proteins/immunology , Fibrinolysis/immunology , Nasal Mucosa/immunology , Rhinitis, Allergic, Seasonal/immunology , Adult , Female , Humans , Kinetics , Male , Mast Cells/immunology , Matrix Metalloproteinase 9/immunology , Middle Aged , Young AdultSubject(s)
Antigens, Dermatophagoides/administration & dosage , Asthma/immunology , Asthma/therapy , Pyroglyphidae/immunology , Sublingual Immunotherapy , Animals , Antigens, Dermatophagoides/immunology , Asthma/pathology , Double-Blind Method , Female , Humans , Male , Nasal Mucosa/immunology , Nasal Mucosa/pathologyABSTRACT
PURPOSE OF REVIEW: Complementary and alternative medicine (CAM) use is widespread across the world. Patients with asthma and allergy regularly use CAM therapies. Allergic and anaphylactic reactions to CAM have been reported. RECENT FINDINGS: Recent attempts to regulate and monitor adverse reaction to these therapies have given us further insight into potential causes of severe allergic reactions. Several culprits identified including Andrographis paniculata, Echinacea species, bee products, Ginkgo biloba and Ginseng are discussed here. SUMMARY: Knowing the factors that increase the risk of anaphylaxis allows reactions to be recognized, reported and further investigated. Research to identify key causative allergens is necessary in the future. Collaboration between the allergy community and CAM practitioners can allow better understanding of allergy to these therapies.
